of the world. The Inter-Ministerial Working Group on Utilisation and Conservation of Energy has assessed a potential for 25 per cent saving of energy in the industrial sector by introducing energy conservation measures.

Unintended benefit on Doxyedline and Gentamycin

2865. DR. JOSEPH LEON D'SOUZA: Will the Minister of INDUSTRY be pleased to refer to the answer *to* Unstarred Question 2314 given in the Rajya Sabha on the 19th August, 1985 and state:

(a) what is the name of each formulator in whose favour amount has been worked out as unintended benefit made on Doxy-cycline and Gentamycin alongwith the details of quantity of each and price difference per kg, as well as the total amount against each formulator;

(b) when was the amount communicated to each formulator and whether any recovery has been made;

(c) if so, the name of each company item involved and amount recovered from each;

(d) whether it is a fact that Gentamycin and Doxycycline are available at much cheaper prices than the notified prices and the formulators are continuing making un-intended benefits;

(e) if so, what is the present market price of each formulation; and

(f) what are the details of steps taken by Government to see that the benefit of price control reaches the consumer rather than allowing the drug formulators to make unintended benefits?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R- K. JAI-CHANDRA SINGH): (a) to (c) Names of the companies who have been given notices for recovery of the difference between price allowed in the formulations and actual import | procurement price of Gentamycin and Doxycycline have already been furnished in reply *to* Rajya Sabha Unstarred Question No. 2314 answered on 19th August, 1985. The elaborate process of scrutinising the invoices so as to work out the amount due from each company is on.

An amount of 194.62 lakhs as due into the Drug Prices Equalisation Account was communicated to M|s. Fulford India Ltd. in regard to Gentamycin. This company filed a writ petition in the Delhi High Court and obtained stay to the recovery.

No amount has so far been recovered from any formulator in respect of Gentamycin and Doxycycline.

(d) and (e) The price notified by the Government is the maximum sale price and the manufacturers are free to sell bulk drugs and formulations at prices not exceeding the prices fixed by the Government. A Statement showing the leader prices °f Doxycycline and Gentamycin formulations as currently in vogue is attached.

(f) Price Control on drugs under the Drugs (Prices Control) Order has helped to moderate the prices and the benefit has flowed to the consumer.

Statement

	Name of the formulation and strength	Pack Size	Leader price excluding Excise Duty as fixed by the Government
1	2	3	4
1	Doxycycline Capsules 100mg./Capsule . .	2 Caps	4·51
		3 Caps	6·27
		4 Caps	6·87
		6 Caps.	7 54
		10's Strip	17·18

1	2	3	4
2	Doxycycline Dry Syrup 15mg/5ml.	25ml Bottle	5·32
3	Doxycycline Injection 50mg./ml	10ml Vial	9·68
		2ml Amp.	2·52
4	Doxycycline injection 100mg/5ml.	5ml Vial	4.38
5	Doxycycline Hcl. Ointment 0.5%	15gm. tube	10·06
6	Gentamycin Injection 40mg./ml	2ml Vial	7·05
7	Gentamycin Eye/Ear Drops 0.3%	3ml vial	3·20
8	Gentamycin Topical Cream 0.1%	5 gm. tube	1·84

Shortage of drags

2866. DR JOSEPH LEON D'SOUZA: Will the Minister of INDUSTRY be pleased to refer to answer to the Unstarred ion 890 given in the Rajya Sabha on the 25th November, 1985 and state:

(a) names of bulk drugs based on which Government received reports of shortages of drug$_s$ from 1st January, 1985 to 30th November, 1985;

(b) names of ihe producers of those drugs as well as five major formulators of each drag;

(c) how many of these drug$_s$ fall under th$_e$ delicensing list along with the names of the companies who submitted proposals for registration of these drugs under de-licensing scheme, and

(d) names of companies and drug$_s$ whose proposals have bee$_n$ registered?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JATCHANDRA SINGH): (a) Reports received during the period revealed localised shortages of some branded products. The concerned manufacturers were advised to rush the stock. No general shortages have been reported during the period in question.

(b) to (d) Do not arise.

Capacity utilisation. of DMT Plant

2867. SHRI SHANKER SINH VAGHELA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the DMT Plant in the private sector is a second Land plant which was installed long before bit by bit and hardly worked at its full capa-city fo$_r$ about two weeks only;

(b) how many year$_s$ that plant remained inoperative before it was sent to India;

(c) whether the low. outdated technology of the plant ha$_s$ anything to do for its present low quality and low level of production; and

(d) what are the details of its working at present?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAJCHANDRA SINGH): (a) The import of second hand DMT plant wa$_s$ permitted in accordance with the import policy prevalent at the time of import. As per the chartered Engineers' certificate the life of the second hand plant would be more than 10 years provided it is operated and maintained according to the internationally accepted standards and processing and operating instructions provided by the forelgn suppliers.

(b) About 5 years.